On Monday, Cognition Therapeutics Inc (NASDAQ: CGTX) was -5.64% drop from the session before settling in for the closing price of $0.63. A 52-week range for CGTX has been $0.34 – $2.95.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
When this article was written, the company’s average yearly earnings per share was at 4.46%. With a float of $33.64 million, this company’s outstanding shares have now reached $40.81 million.
The firm has a total of 28 workers. Let’s measure their productivity. In terms of profitability, gross margin is 48.66%, operating margin of -15707.53%, and the pretax margin is -9212.37%.
Cognition Therapeutics Inc (CGTX) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Cognition Therapeutics Inc stocks. The insider ownership of Cognition Therapeutics Inc is 19.04%, while institutional ownership is 11.38%. The most recent insider transaction that took place on Jan 31 ’25, was worth 30,001. In this transaction CEO & President of this company bought 38,851 shares at a rate of $0.77, taking the stock ownership to the 38,851 shares. Before that another transaction happened on Mar 14 ’24, when Company’s CEO & President bought 5,700 for $1.75, making the entire transaction worth $9,975. This insider now owns 291,345 shares in total.
Cognition Therapeutics Inc (CGTX) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.13 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 4.46% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 9.38% during the next five years compared to -21.09% drop over the previous five years of trading.
Cognition Therapeutics Inc (NASDAQ: CGTX) Trading Performance Indicators
You can see what Cognition Therapeutics Inc (CGTX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.11.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.96, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach -0.61 in one year’s time.
Technical Analysis of Cognition Therapeutics Inc (CGTX)
Analysing the last 5-days average volume posted by the [Cognition Therapeutics Inc, CGTX], we can find that recorded value of 0.71 million was lower than the volume posted last year of 1.22 million. As of the previous 9 days, the stock’s Stochastic %D was 13.85%. Additionally, its Average True Range was 0.07.
During the past 100 days, Cognition Therapeutics Inc’s (CGTX) raw stochastic average was set at 27.28%, which indicates a significant increase from 6.70% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 69.39% in the past 14 days, which was lower than the 107.37% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.6287, while its 200-day Moving Average is $1.0451. Now, the first resistance to watch is $0.6378. This is followed by the second major resistance level at $0.6763. The third major resistance level sits at $0.7034. If the price goes on to break the first support level at $0.5722, it is likely to go to the next support level at $0.5451. Should the price break the second support level, the third support level stands at $0.5066.
Cognition Therapeutics Inc (NASDAQ: CGTX) Key Stats
There are 41,548K outstanding shares of the company, which has a market capitalization of 24.89 million. As of now, sales total 0 K while income totals -25,790 K. Its latest quarter income was 0 K while its last quarter net income were -9,940 K.
